The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice

被引:22
作者
Clinchy, B
Gazdar, A
Rabinovsky, R
Yefenof, E
Gordon, B
Vitetta, ES
机构
[1] Univ Texas, SW Med Ctr, Ctr Canc Immunobiol, Dallas, TX 75235 USA
[2] Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
[4] Carolinas Med Ctr, Charlotte, NC 28203 USA
关键词
breast cancer; in vivo tumor models; Her-2/neu; metastasis; SCID mice; soluble Her-2;
D O I
10.1023/A:1006494001861
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER-2/neu is overexpressed on a variety of human adenocarcinomas and overexpression has been associated with a poor prognosis. For this reason, HER-2 has become an attractive target for immunotherapy. To facilitate testing of anti-HER-2-monoclonal antibodies (MAbs) and immunotoxins (ITs), we have evaluated the in vivo growth and metastatic spread of three HER-2-overexpressing human breast cancer cell lines (BT474, MDA-MB-453 and HCC1954) and one ovarian cancer cell line (SKOV3.ip1) in pre-irradiated male SCID mice using subcutaneous (s.c.), intravenous (i.v.) and intraperitoneal (i.p.) routes of injection. All the cell lines tested grew as s.c. tumors and the growth of BT474 and MDA-MB-453 cells after s.c. injection was improved by co-inoculation with Matrigel. Metastases to the lungs were detectable by PCR or histopathology after s.c. injection of BT474 and to a much lesser extent after s.c. injection of HCC1954, MD-MB-453 and SKOV3.ip1cells. I.P. injection of HCC1954 and SKOV3.ip1 cells produced fatal ascites while i.v. injection of SKOV3.ip1, but not BT474 or MDA-MB-453 cells, resulted in infiltration of lungs and death within 9-11 weeks.
引用
收藏
页码:217 / 228
页数:12
相关论文
共 54 条
  • [1] ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION
    ARTEAGA, CL
    HURD, SD
    WINNIER, AR
    JOHNSON, MD
    FENDLY, BM
    FORBES, JT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) : 2569 - 2576
  • [2] Bai X, 1997, CLIN CHEM, V43, P1843
  • [3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
  • [4] Baselga J, 1998, CANCER RES, V58, P2825
  • [5] EVIDENCE OF FUNCTIONAL LYMPHOCYTES IN SOME (LEAKY) SCID MICE
    BOSMA, GC
    FRIED, M
    CUSTER, RP
    CARROLL, A
    GIBSON, DM
    BOSMA, MJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) : 1016 - 1033
  • [6] Brodowicz T, 1997, INT J CANCER, V73, P875, DOI 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO
  • [7] 2-3
  • [8] BREAST TUMOR-CELL LINES FROM PLEURAL EFFUSIONS
    CAILLEAU, R
    YOUNG, R
    OLIVE, M
    REEVES, WJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 53 (03) : 661 - 674
  • [9] TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE
    COUSSENS, L
    YANGFENG, TL
    LIAO, YC
    CHEN, E
    GRAY, A
    MCGRATH, J
    SEEBURG, PH
    LIBERMANN, TA
    SCHLESSINGER, J
    FRANCKE, U
    LEVINSON, A
    ULLRICH, A
    [J]. SCIENCE, 1985, 230 (4730) : 1132 - 1139
  • [10] DESANTES K, 1992, CANCER RES, V52, P1916